Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 11
Submit an article Journal homepage
5,632
Views
12
CrossRef citations to date
0
Altmetric
Original Articles

Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma

Ying C. Oua BeiGene USA, Inc, San Mateo, CA, USACorrespondence[email protected]
View further author information
,
Zhiyu Tanga BeiGene USA, Inc, San Mateo, CA, USAView further author information
,
William Novotnya BeiGene USA, Inc, San Mateo, CA, USAView further author information
,
Aileen Cohena BeiGene USA, Inc, San Mateo, CA, USAView further author information
,
Kun Wangb Shanghai Qiangshi Information Technology Co., Ltd, Shanghai, ChinaView further author information
,
Lucy Liub Shanghai Qiangshi Information Technology Co., Ltd, Shanghai, ChinaView further author information
,
Yuying Gaob Shanghai Qiangshi Information Technology Co., Ltd, Shanghai, ChinaView further author information
&
Srikumar Sahasranamana BeiGene USA, Inc, San Mateo, CA, USAView further author information
 show all
Pages 2612-2624 | Received 02 Mar 2021, Accepted 03 May 2021, Published online: 23 Jun 2021

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.